Publications by authors named "Benoit Callendret"

Claim this Profile
I
Influenza and COVID-19 Multicomponent Vaccine in Adults-Reply.
Amanda K Rudman Spergel, Benoit Callendret, Lusine Kostanyan

JAMA· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adenovectored RSV prefusion glycoprotein + soluble glycoprotein combination immunization establishes persistent opsonophagocytic antibody response through IgG3.
Xin Tong, Ross Blanc, Deniz Cizmeci, Hadar Malca, Jaewon Kang, Benoit Callendret

Front Immunol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 study of an Ad26.RSV.preF/RSV preF protein vaccine to evaluate the prevention efficacy of RSV-mediated lower tract disease, immunogenicity and safety in Japanese adults.
Hiroshi Tamura, Atsushi Momose, Yumi Takato, Zheng Richuan, Arangassery Rosemary Bastian, Benoit Callendret

Respir Investig· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years: A Randomized Clinical Trial.
Amanda K Rudman Spergel, Iris Wu, Weiping Deng, Jose Cardona, Kimball Johnson, Benoit Callendret

JAMA· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.
Archana Jastorff, Efi Gymnopoulou, Jose Salas, Elizabeth Merrall, Erik Buntinx, Benoit Callendret

Vaccine· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life.
Tessa Hosman, Roy van Heesbeen, Arangassery Rosemary Bastian, Weihong Hu, Christy Comeaux, Benoît Callendret

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material.
Archana Jastorff, Arangassery Rosemary Bastian, Nynke Ligtenberg, Vladislav Klyashtornyy, Benoît Callendret

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study.
Roy van Heesbeen, Arangassery Rosemary Bastian, Edmund Omoruyi, Jeffrey Rosen, Christy A Comeaux, Benoit Callendret

Vaccine· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ad26.RSV.preF completely protects calves from severe respiratory disease induced by bovine RSV challenge.
Leslie van der Fits, Rineke de Jong, Karin Dijkman, Marjolein Heemskerk-van der Meer, Lisanne Tettero, Benoit Callendret

NPJ Vaccines· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study.
Ann R Falsey, Tessa Hosman, Arangassery Rosemary Bastian, Sjouke Vandenberghe, Eric K H Chan, Benoit Callendret

Lancet Infect Dis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months.
Joanne M Langley, Terry M Nolan, Mika Rämet, Peter C Richmond, Nelson Rosário Filho, Benoit Callendret

Open Forum Infect Dis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial.
Widagdo Widagdo, Arangassery Rosemary Bastian, Archana M Jastorff, Ilse Scheys, Els De Paepe, Benoit Callendret

J Infect Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF-Based Regimen in Japanese Adults Aged 60 Years and Older.
Takashi Eto, Yusuke Okubo, Atsushi Momose, Hiroshi Tamura, Richuan Zheng, Benoit Callendret

Influenza Other Respir Viruses· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.
Christy A Comeaux, Stephan Bart, Arangassery Rosemary Bastian, Vladislav Klyashtornyy, Els De Paepe, Benoit Callendret

J Infect Dis· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine.
Yannic C Bartsch, Deniz Cizmeci, Dansu Yuan, Nickita Mehta, Jeroen Tolboom, Benoit Callendret

J Virol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans.
Chelsea McLean, Karin Dijkman, Auguste Gaddah, Babajide Keshinro, Michael Katwere, Benoit Callendret

Front Immunol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of symptoms in respiratory syncytial virus infection in adults: psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire™ symptom scores.
Richard H Osborne, Lauren M Nelson, Sheri Fehnel, Nicole Williams, Randall H Bender, Benoit Callendret

J Patient Rep Outcomes· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models.
Eirikur Saeland, Leslie van der Fits, Renske Bolder, Marjolein Heemskerk-van der Meer, Joke Drijver, Benoit Callendret

NPJ Vaccines· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models.
Freek Cox, Eirikur Saeland, Anne Thoma, Ward van den Hoogen, Lisanne Tettero, Benoit Callendret

Vaccines (Basel)· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.
Ann R Falsey, Kristi Williams, Efi Gymnopoulou, Stephan Bart, John Ervin, Benoit Callendret

N Engl J Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.
Arabella S V Stuart, Miia Virta, Kristi Williams, Ilkka Seppa, Robyn Hartvickson, Benoit Callendret

J Infect Dis· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries.
Jonathan S Nguyen-Van-Tam, Maureen O'Leary, Emily T Martin, Esther Heijnen, Benoit Callendret

Eur Respir Rev· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody effector functions are associated with protection from respiratory syncytial virus.
Yannic C Bartsch, Deniz Cizmeci, Jaewon Kang, Tomer Zohar, Sivakumar Periasamy, Benoit Callendret

Cell· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
Viki Bockstal, Maarten Leyssen, Dirk Heerwegh, Bart Spiessens, Cynthia Robinson, Benoit Callendret

NPJ Vaccines· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
Viki Bockstal, Georgi Shukarev, Chelsea McLean, Neil Goldstein, Stephan Bart, Benoit Callendret

PLoS One· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis